Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Instil Bio Inc TIL

Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. Its first such program is an engineered tumor infiltrating lymphocyte (TIL), cell therapy for the treatment of cancer. It is engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR), platform. The Company's lead CoStAR-TIL product candidate, ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (Fra), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer. CAR-T and TCR-T therapies are cell products composed of T cells that have been genetically engineered to recognize a specific cancer-related antigen on the surface of tumor cells.


NDAQ:TIL - Post by User

Bullboard Posts
Comment by Goldmetalon Aug 24, 2011 10:36am
293 Views
Post# 18974477

RE: RE: RE: William Sheriff CEO Golden Predator

RE: RE: RE: William Sheriff CEO Golden Predator This is the schedule from last nights e-mail. Looks like they may have changed the times slightly.Wednesday's AM Guest Line Up7:10 AM - Sarkozy SpeaksJan Lambregts, Global Head of Financial Markets Research, Rabobank7:50 AM - BHP ReportsErnie Lalonde, Senior Vice President, Mining, DBRS8:15 AM - Commodities IndexPatricia Mohr, Vice President, Economics, Scotiabank8:30 AM - U.S. Durable GoodsTim Quinlan, Economist, Wells Fargo Securities9:15 AM - Market LookaheadPatrick Kim, Partner, Georgian Capital Partners 9:45 AM - U.S. Equity StrategyMatt McCall, President, Penn Financial Group10:05 AM - Sarkozy's Deficit-Cutting MeasuresSilvio Peruzzo, Euro-Area Economist, RBS10:30 AM - Oil InventoriesCarl Larry, Director, Energy Derivatives and Research, Blue Ocean Brokerage10:35 AM - The New Yukon Gold RushWilliam Sheriff, CEO, Golden Predator10:40 AM - Arctic Special: Climate Change & Industry OpportunityLouis Fortier, Scientific Director, ArcticNet11:05 AM - Fund TrackerMark Serdan, VP & Portfolio Manager, BMO Asset Management, and Manager, BMO Precious Metals Fund11:30 AM - The Pitch with Andrew Bell
Bullboard Posts